Profitability
Weight: 20%
B-
65
- 5yr Avg ROIC 8.1%
- Operating Margin Trend +2.67 pp/yr
AMRX
Amneal Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -155.1%
- 5yr Share-Count CAGR 16.9%
Growth Quality
Weight: 15%
C
54
- 5yr Revenue CAGR 8.7%
- 5yr EPS CAGR -18.5%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 15%
C+
62
- 5yr FCF Margin 7.3%
- 5yr FCF/NI Conversion 11.01x
Balance Sheet
Weight: 20%
D-
33
- Net Debt / EBITDA 4.02x
- Interest Coverage (EBIT/Int) 1.58x
- Altman Z-Score 2.35
Stability
Weight: 15%
C
54
- EPS Volatility (σ/μ) 0.73
- Negative-Revenue Years (5) 0/5
- Piotroski F-Score 7
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 3 gurus held; 1 trimmed; 2 full exits.
- Holders
- 1 -2
- Avg Δ position
- -55.0%
- New buys
- 0
- Full exits
- 2
- Greenblatt sold -100%
- Wood sold -100%
- Cooperman decreased -55%